ADL Amdl,

TUSTIN, Calif., Jan. 11 /PRNewswire-FirstCall/ -- AMDL (AMEX:ADL) announced today that its Chinese subsidiary, Jade Pharmaceutical Inc., has begun production of the antibiotic levofloxacin, which is part of the top selling class of drugs in China, and which is used to treat bacterial infections including pneumonia, urinary tract, kidney and skin infection. Levofloxacin is marketed in the U.S. by a major pharmaceutical company. Antibiotic drugs sales in China exceeded $4.8 billion (U.S.) in 2003 and growth is estimated at 20 percent annually. Levofloxacin is an advanced generation fluoroquinolone antibiotic and has proven its efficacy and safety globally with more than 12 years of usage. Jade Pharmaceutical recently received approval for the product from the China State Food and Drug Administration. "Jade Pharmaceuticals is producing levofloxacin at the Jiangxi Jade Biochemistry Ltd. manufacturing facility in the South China City of Shargro in the Jiangxi Province of China and, at present, this product will only be sold in the People's Republic of China, said Gary Dreher, AMDL CEO. That facility recently was reapproved for meeting worldwide GMP standards of manufacture. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc. is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright